Fluorescence in Situ Hybridization Testing Can Identify the Amplification of MDM2 in 8.5% of Superficial Large Lipomatous Lesions as Atypical Lipomatous Tumors Without Morphologic Abnormalities

Authors

Allison K. Kennedy, Corewell Health East
Christopher K. Hysell, Corewell Health East
Joy M. Roman, Corewell Health East
Shelly L. Kaufman, Corewell Health East
Mark A. Micale, Corewell Health East
Ping L. Zhang, Corewell Health East

Document Type

Conference Proceeding - Restricted Access

Publication Date

8-2025

Publication Title

Archives of Pathology and Laboratory Medicine

Volume

149

Issue

8

First Page

e263

Comments

College of American Pathologists 2025 Annual Meeting (CAP25), September 13-16, 2025, Orlando, FL

Last Page

e263

Recommended Citation

Kennedy AK, Hysell CK, Roman JM, Kaufman SL, Micale MA, Zhang PL. Fluorescence in situ hybridization testing can identify the amplication of MDM2 in 8.5% of superficial large lipomatous lesions as atypical lipomatous tumors without morphologic abnormalities. Arch Pathol Lab Med. 2025 Aug; 149(8):e263. doi:10.5858/arpa.2025-0194-AB

DOI

10.5858/arpa.2025-0194-AB